http://www.prnewswire.com/news-rele...s-patients-using-insulin-pumps-119885379.html
"The initial results from Halozyme's first pump study show that the faster pharmacokinetic and glucodynamic findings consistently demonstrated with mealtime subcutaneous insulin injections are also observed in the CSII setting," stated Doug Muchmore, M.D., vice president of endocrinology clinical development. "The ultrafast profile of analog insulin with rHuPH20 is well suited for use with insulin pumps."
"The initial results from Halozyme's first pump study show that the faster pharmacokinetic and glucodynamic findings consistently demonstrated with mealtime subcutaneous insulin injections are also observed in the CSII setting," stated Doug Muchmore, M.D., vice president of endocrinology clinical development. "The ultrafast profile of analog insulin with rHuPH20 is well suited for use with insulin pumps."
